Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bermekimab for Moderate to Severe Hidradenitis Suppurativa
jRCT2031210308Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of bermekimab in hidradenitis suppurativa (HS) (7 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: HiSCR50 response at Week 16 (Part 1) and HiSCR50 response at Week 12 (Part 2). Started Jan 2022; status: completed.
02
Drugs
bermekimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2031210308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210308.